Reviewing Aileron Therapeutics Inc. (ALRN)’s and Halozyme Therapeutics Inc. (NASDAQ:HALO)’s results

We are comparing Aileron Therapeutics Inc. (NASDAQ:ALRN) and Halozyme Therapeutics Inc. (NASDAQ:HALO) on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aileron Therapeutics Inc. N/A 0.00 31.17M -2.14 0.00
Halozyme Therapeutics Inc. 177.94M 12.83 51.07M -0.36 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Aileron Therapeutics Inc. 0.00% 0% 0%
Halozyme Therapeutics Inc. -28.70% -20.4% -11.4%


The Current Ratio and Quick Ratio of Aileron Therapeutics Inc. are 3.1 and 3.1 respectively. Its competitor Halozyme Therapeutics Inc.’s Current Ratio is 2.9 and its Quick Ratio is 2.7. Aileron Therapeutics Inc. can pay off short and long-term obligations better than Halozyme Therapeutics Inc.

Analyst Recommendations

The Ratings and Recommendations for Aileron Therapeutics Inc. and Halozyme Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aileron Therapeutics Inc. 0 0 2 3.00
Halozyme Therapeutics Inc. 1 0 2 2.67

Aileron Therapeutics Inc. has a 593.64% upside potential and a consensus target price of $6. On the other hand, Halozyme Therapeutics Inc.’s potential upside is 33.50% and its average target price is $21. The results provided earlier shows that Aileron Therapeutics Inc. appears more favorable than Halozyme Therapeutics Inc., based on analyst belief.

Institutional & Insider Ownership

Aileron Therapeutics Inc. and Halozyme Therapeutics Inc. has shares held by institutional investors as follows: 23.9% and 87.7%. Aileron Therapeutics Inc.’s share held by insiders are 77.03%. On the other hand, insiders held about 0.6% of Halozyme Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aileron Therapeutics Inc. -18.04% -26.29% -37.68% -35.5% -76.33% 53.57%
Halozyme Therapeutics Inc. -5.45% -5.22% -4.88% -0.63% -20.53% 7.93%

For the past year Aileron Therapeutics Inc.’s stock price has bigger growth than Halozyme Therapeutics Inc.


On 8 of the 11 factors Aileron Therapeutics Inc. beats Halozyme Therapeutics Inc.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.